Last updated on December 2019

CemiplimAb Survivorship Epidemiology


Brief description of study

The objectives of the study are:

  • To identify potential determinants of disease progression, Quality of life (QOL), and other health-related outcomes for patients with Cutaneous squamous cell carcinoma (CSCC) undergoing treatment with cemiplimab
  • To assess patient experience, including QOL and functional status, in a real-world setting for patients with CSCC
  • To identify and describe long-term effects of treatment of patients with CSCC
  • To collect and describe serious adverse event (SAE) and immune-related adverse event (irAE) data on study participants
  • To describe patients who receive cemiplimab as treatment for CSCC in a real-world setting
  • To describe real-world use patterns of cemiplimab for CSCC
  • To assess the long-term effectiveness of cemiplimab in CSCC patients in a real-world setting
  • To assess the effectiveness of cemiplimab as a first-line (1L) or later systemic treatment in patients with Advanced and metastatic cutaneous squamous cell carcinoma (aCSCC), regardless of etiology
  • To assess the effectiveness of cemiplimab in immunosuppressed and immunocompetent patients with a CSCC, regardless of etiology
  • To assess the effectiveness of cemiplimab after prior exposure to radiation therapy for CSCC

Clinical Study Identifier: NCT03836105

Find a site near you

Start Over

Regeneron Research Facility

Delray Beach, FL United States
0.53miles
  Connect »